Page 336 - Glucose Monitoring Devices

Sensor Guardian 3 Guardian 3 Dexcom G6 Guardian 3 (continued)

Hormone Insulin (FiAsp), Glucagon, Pramlintide Insulin (FiAsp) Insulin Insulin Insulin, Glucagon Insulin
2019.dcont’d device

July Infusion 670G 670G iAPS Bihormonal bionic pancreas versus insulin only bionic pancreas versus usual care 670G HCL with Fiasp versus 670G HCL with Novolog
and
May

between Intervention control versus Triple hormone CL (insulin, glucagon, pramlintide) without meal announcements versus insulin only CL FiAsp versus aspart HCL 3 mos versus HCL 4 wks versus standard of care HCL versus SAP/ PLGS Bihormonal CL versus HCL versus usual care (pump or injections) FiAsp versus Novolog

recruiting

as studies Environment Inpatient Outpatient Outpatient Outpatient Outpatient Outpatient
listed Pediatric

were Age (years) 18þ 18þ 18þ 18þ 18þ 18þ

that (per
ClinicalTrials.gov Duration arm) 27 h 4wk 3mo 4wk 7d 7wk

on design
listed Study Randomized Crossover Clinical trial Randomized Double-blinded Crossover Clinical trial Randomized Single-blinded Parallel group Clinical trial Randomized crossover Randomized Open label Crossover Randomized Open label Crossover

studies

Closed-loop Title Triple-hormone (insulin-pramlintide- glucagon) closed- loop strategy to regulate glucose levels without carbohydrate counting Evaluation of Fiasp (fast acting insulin aspart) in 670G hybrid closed-loop therapy Mechanisms for the restoration of hypoglycemia awareness Model predictive control (MPC) artificial pancreas versus sensor- augmented pump (SAP)/predictive low gluc

16.1 trial NCT03800875 NCT03554486 NCT03738852 NCT03767790 NCT03258853 NCT03977727

Table Clinical ID